HUTCHMED (China)

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Biotech

News

Health Care

Movers

Trading Ideas

General

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025.

Chinese Cancer Drug Developer Hutchmed Sharpens R&amp;D Focus, Divests Non-Core JV For Over $600 Million

Intraday Update

Markets

ALHC

AZTA

BRKR

FLEX

GLBE

KEYS

NOVA

RCAT

RERE

TKNO

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday

Asia

Key Takeaways:


	Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla
	The company plans to focus on innovative drugs and said it might give up its traditional Chinese medicine business


　

By Molly Wen

Hutchmed scores U.S. success with cancer drug, but profits still dip

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Press Releases

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Financing

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED to Announce 2024 Final Results

IVBIY

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Wave Life Sciences Ltd. - Ordinary Shares

Comments

HUTCHMED (China)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga